Treatment of acute schizophrenia with paliperidone ER: Predictors for treatment response and benzodiazepine use

Heres, Stephan; Don, Liana; Herceg, Miroslav; Bidzan, Leszek; Blanc, Michel; Siracusano, Alberto; Mačiulis, Valentinas; Lahaye, Marjolein; Schreiner, A.

doi:10.1016/j.pnpbp.2013.09.015

Cited by 14 publications

(22 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22,26,33,34 The CGI-S responder criteria in the open-label portion (≥ 1 point improvement) has been utilized in other areas of psychiatry including schizophrenia. 36 The use of the CGI-C and CGI-S clinician rating efficacy measures have been previously compared. 37,38 Forkman et al reported comparable results between the CGI-C and CGI-S scales; however, they noted that both scales lacked congruence with patient ratings, and as a result, the authors suggested a variety of patient-and clinical-rated scales be incorporated in clinical trial designs.…”

Section: Discussionmentioning

confidence: 99%

Armodafinil for the Treatment of Excessive Sleepiness Associated with Mild or Moderate Closed Traumatic Brain Injury: A 12-Week, Randomized, Double-Blind Study followed by a 12-Month Open-Label Extension

Menn¹,

Yang

Lankford

2014

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

Objective: To evaluate the effi cacy and tolerability of armodafi nil in patients with excessive sleepiness following mild or moderate closed traumatic brain injury (TBI). S C I E N T I F I C I N V E S T I G A T I O N SE ach year, approximately 1.7 million people in the US experience a traumatic brain injury (TBI), 1 of which 75% are classifi ed as mild in severity.2 Sleep disturbances including obstructive sleep apnea, hypersomnia, insomnia, periodic limb movement, and narcolepsy have all been reported among patients with TBI.3-5 Excessive sleepiness-or the more broad condition of hypersomnia-is particularly common among post acute TBI patients, ranging from 25% to 53% depending on the defi nitions of the condition and assessments employed.4,6-8 This is considerably greater than the rate of excessive sleepiness reported in the general population (4.0% to 20.6%). 9The appreciable effects of sleep disorders on the TBI population are not fully known, although some evidence suggests that they may contribute to cognitive impairment, mood disturbance, and disrupt recovery or rehabilitation. 4,[10][11][12][13] Despite the high prevalence of hypersomnia in the TBI population, the literature is sparse regarding treatment recommendations. Recommended strategies include addressing any underlying medical or psychiatric conditions (e.g., nasal continuous positive

show abstract

Section: Discussionmentioning

confidence: 99%

Armodafinil for the Treatment of Excessive Sleepiness Associated with Mild or Moderate Closed Traumatic Brain Injury: A 12-Week, Randomized, Double-Blind Study followed by a 12-Month Open-Label Extension

Menn¹,

Yang

Lankford

2014

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

show abstract

“…The primary outcome measures are treatment response,555657 remission,58 recovery,65960 and relapse;61 the definitions of these variables are summarized in Table 1. The recovery criteria will be adjusted for all participants.…”

Section: Methodsmentioning

confidence: 99%

Design and Methodology of the Korean Early Psychosis Cohort Study

Kim

Lee

Kim

et al. 2017

Psychiatry Investig

View full text Add to dashboard Cite

The present study details the rationale and methodology of the Korean Early Psychosis Cohort Study (KEPS), which is a clinical cohort investigation of first episode psychosis patients from a Korean population. The KEPS is a prospective naturalistic observational cohort study that follows the participants for at least 2 years. This study includes patients between 18 and 45 years of age who fulfill the criteria for one of schizophrenia spectrum and other psychotic disorders according to the diagnostic criteria of DSM-5. Early psychosis is defined as first episode patients who received antipsychotic treatment for fewer than 4 consecutive weeks after the onset of illness or stabilized patients in the early stages of the disorder whose duration of illness was less than 2 years from the initiation of antipsychotic treatment. The primary outcome measures are treatment response, remission, recovery, and relapse. Additionally, several laboratory tests are conducted and a variety of objective and subjective psychiatric measures assessing early life trauma, lifestyle pattern, and social and cognitive functioning are administered. This long-term prospective cohort study may contribute to the development of early intervention strategies and the improvement of long-term outcomes in patients with schizophrenia.

show abstract

“…Tsutsumi et al [22,23,24] reported that the treatment continuation rate with BNS in acute-phase schizophrenia patients varied with the use of adjuvant drugs. Moreover, Heres et al [19] reported that in the PERTAIN study, which investigated the efficacy of PAL in acute flare-up schizophrenia patients, Patients with a higher disease severity at baseline were about twice as likely to be treated concomitantly with a Bz. The results of this study and preexisting data reveal different rates of the concomitant use of adjuvant drugs, but the concomitant use of adjuvant drugs in acute-phase treatment is a common approach irrespective of the type of antipsychotic.…”

Section: Positioning Of Adjuvant Drugs and Concomitant Antipsychoticsmentioning

confidence: 99%

Comparative Effectiveness of Blonanserin and Paliperidone in 93 In-patients with Acute- to Maintenance-phase Schizophrenia

Fujita

Bessho

Miyazaki

et al. 2016

CNPT

View full text Add to dashboard Cite

When initiating treatment for acute-phase schizophrenia, careful consideration needs to be given to which drug will be used in the subsequent maintenance phase. Since blonanserin (BNS) and paliperidone (PAL) are both first-line treatments for acute-phase schizophrenia, our study retrospectively investigated the treatment continuation rate, dose levels, use of concomitant medications, clinical effects, and adverse drug reactions in 93 acute-phase schizophrenia patients receiving either of the monotherapies (BNS: n=40, PAL: n=53) to assess the treatment benefit of these drugs in acute-to maintenance-phase schizophrenia. The efficacy endpoints included the clinical global impression of severity (CGI-S), the clinical global impression of improvement (CGI-I) and the global assessment on function (GAF) scores assessed at Weeks 4, 8, 12, 24, and 52 after treatment initiation. Patients requiring involuntary hospitalization accounted for 75% of the BNS group and 90% of the PAL group and mostly comprised patients who had good social function before onset but relapsed because of poor drug adherence and hence received no residual benefit from their earlier treatment, as well as patients who were experiencing their first episode of schizophrenia. There were differences between the treatment groups in gender, age, and duration of illness. Notably, the BNS group had a higher proportion of females than the PAL group. In both groups, the CGI-S and CGI-I responses were affected by treatment in a majority of the patients who continued treatment, and the GAF score at Week 52 recovered to levels comparable to the pre-onset level in patients continuing treatment. The treatment continuation rate in this study (assessed by the Kaplan-Meier method) was 85% in the BNS group and 77% in the PAL group at Week 8 and 60.9% in the BNS group and 50.9% in the PAL group at Week 52. After Week 24, the number of dropouts in the BNS group decreased while the PAL group still had dropouts due to hyperprolactinemia-related adverse drug reactions. Treatment of schizophrenia requires careful selection of drugs in the acute phase that will ensure a good long-term prognosis and good drug adherence in the maintenance phase, and from this perspective, the results of this study suggest that BNS and PAL could be first-line drugs for the entire duration of treatment, from the acute phase to the maintenance phase.

show abstract

Treatment of acute schizophrenia with paliperidone ER: Predictors for treatment response and benzodiazepine use

Cited by 14 publications

References 29 publications

Armodafinil for the Treatment of Excessive Sleepiness Associated with Mild or Moderate Closed Traumatic Brain Injury: A 12-Week, Randomized, Double-Blind Study followed by a 12-Month Open-Label Extension

Armodafinil for the Treatment of Excessive Sleepiness Associated with Mild or Moderate Closed Traumatic Brain Injury: A 12-Week, Randomized, Double-Blind Study followed by a 12-Month Open-Label Extension

Design and Methodology of the Korean Early Psychosis Cohort Study

Comparative Effectiveness of Blonanserin and Paliperidone in 93 In-patients with Acute- to Maintenance-phase Schizophrenia

Contact Info

Product

Resources

About